Reviewing DexCom (NASDAQ:DXCM) and Anteris Technologies Global (NASDAQ:AVR)

DexCom (NASDAQ:DXCM) and Anteris Technologies Global (NASDAQ:AVR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, institutional ownership, earnings and dividends.

Volatility and Risk

DexCom has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Comparatively, Anteris Technologies Global has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500.

Profitability

This table compares DexCom and Anteris Technologies Global’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DexCom	19.31%	33.33%	13.19%
Anteris Technologies Global	-5,148.78%	-124.76%	-101.21%

Institutional and Insider Ownership

97.8% of DexCom shares are held by institutional investors. 0.3% of DexCom shares are held by insiders. Comparatively, 4.5% of Anteris Technologies Global shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares DexCom and Anteris Technologies Global”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.82 billion	5.21	$836.30 million	$2.34	27.82
Anteris Technologies Global	$1.91 million	385.79	-$94.14 million	($2.23)	-3.39

DexCom has higher revenue and earnings than Anteris Technologies Global. Anteris Technologies Global is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and target prices for DexCom and Anteris Technologies Global, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1	3	19	3	2.92
Anteris Technologies Global	1	0	4	0	2.60

DexCom presently has a consensus price target of $82.21, suggesting a potential upside of 26.30%. Anteris Technologies Global has a consensus price target of $16.00, suggesting a potential upside of 111.36%. Given Anteris Technologies Global’s higher probable upside, analysts plainly believe Anteris Technologies Global is more favorable than DexCom.

Summary

DexCom beats Anteris Technologies Global on 12 of the 15 factors compared between the two stocks.

About DexCom

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

About Anteris Technologies Global

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.